Recommendation of the President – Tript-OH and Levotonine (L-5-hydroxytryptophan)
On 20 January 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 28/2026 on the validity of issuing approvals for the reimbursement of the medicinal products Tript-OH and Levotonine (L-5-hydroxytryptophan) for the indication: tetrahydrobiopterin deficiency